Coherus BioSciences (NASDAQ:CHRS) Earns “Buy” Rating from HC Wainwright

Coherus BioSciences (NASDAQ:CHRS)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $12.00 price target on the biotechnology company’s stock.

A number of other research firms have also weighed in on CHRS. StockNews.com lowered shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a research note on Friday, September 6th. Robert W. Baird reduced their price target on shares of Coherus BioSciences from $9.00 to $8.00 and set an “outperform” rating for the company in a research report on Monday, July 1st. Finally, UBS Group cut Coherus BioSciences from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $4.00 to $1.50 in a research report on Friday, August 16th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Coherus BioSciences has an average rating of “Moderate Buy” and an average price target of $6.92.

Coherus BioSciences Stock Up 0.8 %

Coherus BioSciences stock opened at $1.30 on Monday. Coherus BioSciences has a twelve month low of $1.20 and a twelve month high of $4.97. The company has a market capitalization of $149.14 million, a P/E ratio of -1.67 and a beta of 0.66. The stock’s 50 day moving average is $1.44 and its 200 day moving average is $1.83.

Coherus BioSciences (NASDAQ:CHRS) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.10. The company had revenue of $64.98 million during the quarter, compared to analysts’ expectations of $57.08 million. As a group, equities analysts expect that Coherus BioSciences will post -1.07 EPS for the current year.

Hedge Funds Weigh In On Coherus BioSciences

Institutional investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD boosted its stake in shares of Coherus BioSciences by 32.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 30,851 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 7,608 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Coherus BioSciences by 66.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 21,426 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 8,546 shares during the period. Hsbc Holdings PLC lifted its position in Coherus BioSciences by 10.6% during the second quarter. Hsbc Holdings PLC now owns 103,183 shares of the biotechnology company’s stock valued at $179,000 after purchasing an additional 9,905 shares in the last quarter. Jump Financial LLC grew its holdings in Coherus BioSciences by 50.6% during the fourth quarter. Jump Financial LLC now owns 33,267 shares of the biotechnology company’s stock valued at $111,000 after purchasing an additional 11,180 shares during the period. Finally, TrinityPoint Wealth LLC purchased a new stake in Coherus BioSciences in the fourth quarter worth about $40,000. Institutional investors own 72.82% of the company’s stock.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.